Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H28ClN5O3.2ClH |
Molecular Weight | 530.875 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.CN1CCN(CCCCN2C(=O)CN(\N=C\C3=CC=C(O3)C4=CC=C(Cl)C=C4)C2=O)CC1
InChI
InChIKey=HHPSICLSNHCSNZ-BYEGLACWSA-N
InChI=1S/C23H28ClN5O3.2ClH/c1-26-12-14-27(15-13-26)10-2-3-11-28-22(30)17-29(23(28)31)25-16-20-8-9-21(32-20)18-4-6-19(24)7-5-18;;/h4-9,16H,2-3,10-15,17H2,1H3;2*1H/b25-16+;;
Azimilide is a class III antiarrhythmic agent that prolongs cardiac repolarisation by blocking both the rapidly and slowly activating components of the delayed rectifier potassium channel. The most important consequence of this is apparent rate-independent activity, so that, unlike other class III antiarrhythmics, azimilide does not lose efficacy at high heart rates. Azimilide has very predictable pharmacokinetics, is predominantly hepatically metabolized, and has no significant drug interactions with digoxin or warfarin. The most common adverse effects reported by patients on azimilide were approximately equal in frequency with those on placebo: headache, asthenia, infection, diarrhea and dizziness. Azimilide is in phase III clinical trials for the treatment both supraventricular and ventricular tachyarrhythmias.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL240 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11033107 |
610.0 nM [IC50] |
PubMed
Title | Date | PubMed |
---|---|---|
Azimilide dihydrochloride: a unique class III antiarrhythmic agent. | 1999 May-Jun |
|
Effects of azimilide, a new class III antiarrhythmic drug, on reentrant circuits causing ventricular tachycardia and fibrillation in a canine model of myocardial infarction. | 2001 Sep |
|
Influence of coadministration on the pharmacokinetics of azimilide dihydrochloride and digoxin. | 2005 Jul |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14739716
100 and 125 mg once daily
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C93038
Created by
admin on Fri Dec 15 15:55:28 GMT 2023 , Edited by admin on Fri Dec 15 15:55:28 GMT 2023
|
||
|
NCI_THESAURUS |
C47793
Created by
admin on Fri Dec 15 15:55:28 GMT 2023 , Edited by admin on Fri Dec 15 15:55:28 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m2174
Created by
admin on Fri Dec 15 15:55:28 GMT 2023 , Edited by admin on Fri Dec 15 15:55:28 GMT 2023
|
PRIMARY | Merck Index | ||
|
6E6VJP68KR
Created by
admin on Fri Dec 15 15:55:28 GMT 2023 , Edited by admin on Fri Dec 15 15:55:28 GMT 2023
|
PRIMARY | |||
|
C77977
Created by
admin on Fri Dec 15 15:55:28 GMT 2023 , Edited by admin on Fri Dec 15 15:55:28 GMT 2023
|
PRIMARY | |||
|
9571003
Created by
admin on Fri Dec 15 15:55:28 GMT 2023 , Edited by admin on Fri Dec 15 15:55:28 GMT 2023
|
PRIMARY | |||
|
GG-11
Created by
admin on Fri Dec 15 15:55:28 GMT 2023 , Edited by admin on Fri Dec 15 15:55:28 GMT 2023
|
PRIMARY | |||
|
149888-94-8
Created by
admin on Fri Dec 15 15:55:28 GMT 2023 , Edited by admin on Fri Dec 15 15:55:28 GMT 2023
|
PRIMARY | |||
|
SUB25697
Created by
admin on Fri Dec 15 15:55:28 GMT 2023 , Edited by admin on Fri Dec 15 15:55:28 GMT 2023
|
PRIMARY | |||
|
SUB25698
Created by
admin on Fri Dec 15 15:55:28 GMT 2023 , Edited by admin on Fri Dec 15 15:55:28 GMT 2023
|
PRIMARY | |||
|
CHEMBL123558
Created by
admin on Fri Dec 15 15:55:28 GMT 2023 , Edited by admin on Fri Dec 15 15:55:28 GMT 2023
|
PRIMARY | |||
|
100000090568
Created by
admin on Fri Dec 15 15:55:28 GMT 2023 , Edited by admin on Fri Dec 15 15:55:28 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD